COVID-19 vaccines about to be produced in Taizhou!Time of issue : 2020-11-26
On the morning of November 23, the news of the official kick-off of the COVID-19 vaccine industrialization base of Jiangsu Rec-Biotechnology Co., Ltd caught the eyes of the public.
News | RecBio completed series B round financingTime of issue : 2020-11-11
Following the completion of CNY 500 million series A round financing in early 2019, Jiangsu Rec-Biotechnology Co., Ltd (hereinafter referred to as RecBio) recently completed its series B round financing with an amount of over USD 100 million.
A Noah's Ark to combat COVID-19Time of issue : 2020-10-27
The diagnostic reagents section of China Medical City has collectively risen to prominence in the fight against the COVID-19 pandemic, and made outstanding contributions.
Further promote the implementation of IPD system to lay the foundation for a better future of RecBio - Written on the launch of the IPD Phase IITime of issue : 2020-10-27
Our company's ongoing development of the Integrated Product Development (IPD) system is a foundation for RecBio's great cause. IPD is an advanced, scientific and mature system of product development models, concepts and methods.
Professor Lu Shuihua: Don't let down your guards in this "protracted war" against tuberculosis [Eastern Forum on Tuberculosis - Popular Science].Time of issue : 2020-11-09
NEJM: Quadrivalent HPV vaccination can significantly reduce risk of invasive cervical cancer, according to a study of millions of peopleTime of issue : 2020-11-09
Jiangsu Recbio Technology Co., Ltd.
Media Inquiry: email@example.com
Investor Inquiry: firstname.lastname@example.org
Address: Vaccine Engineering Center, China Medical City, Taizhou